Add to a list

Inactive Instrument

Nutriband Inc Stock Other OTC

US67092M1099

Medical Equipment, Supplies & Distribution

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	37.81M 33.03M 30.56M 28.52M 53.54M 3.57B 53.93M 363M 141M 1.76B 142M 139M 6.1B	P/E 2025	-8.39x	P/E 2026	-1.86x
Enterprise Value	33.48M 29.25M 27.06M 25.25M 47.41M 3.16B 47.76M 322M 125M 1.56B 126M 123M 5.4B	EV / Sales 2025	41.1x	EV / Sales 2026	26.5x
Free-Float	28.27%	Yield 2025 *	-	Yield 2026	-

06-11	Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2026	CI
05-31	Nutriband Inc. announced that it has received $5 million in funding	CI
05-15	Active Intelligence and Nutriband Inc. Showcases Expanding Ai Wellness Product Portfolio and Announces New June Product Launches At Ecrm Conference	CI
04-29	Nutriband Inc. Reports Earnings Results for the Full Year Ended January 31, 2026	CI
03-18	Nutriband Ai Kinesiology Tapes Approves for Distribution and Sale in Costa Rica	CI
03-18	Nutriband Ai kinesiology tapes approved for distribution and sale in Costa Rica	RE
02-17	Nutriband Signs Exclusive Distribution Agreement with Innomedica for Aversa Fentanyl and All Sports Tape Products for Costa Rica	CI
02-17	Nutriband signs exclusive distribution agreement with Innomedica for Aversa fentanyl	RE
02-12	EarthVision Bio Solutions Inc. cancelled the acquisition of 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc..	CI
02-03	Nutriband Inc. Announces Election of New Directors	CI
01-30	Nutriband Inc.'s Equity Buyback announced on September 18, 2024, has expired.	CI
12-29	EarthVision Bio Solutions Inc. signed an agreement to acquire 90% stake in Pocono Pharmaceuticals, Inc. from Nutriband Inc. for $5 million.	CI
12-18	Nutriband signs letter of intent with Qvanta Group of Companies	RE

05-15	Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference	GL
04-29	Nutriband : Annual Report for Fiscal Year Ending January 31, 2026 (Form 10-K)	PU
04-22	Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast	GL
03-30	Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch	GL
03-18	Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica	GL

Manager	Title	Age	Since
Gareth Sheridan CEO	Chief Executive Officer	35	2015-12-31
Serguei Melnik CEO	Chief Executive Officer	52	-
Gerald Goodman DFI	Director of Finance/CFO	77	2020-09-01

Director	Title	Age	Since
Serguei Melnik CHM	Chairman	52	2022-01-20
Stefan Mancas BRD	Director/Board Member	48	2018-06-30
Gareth Sheridan BRD	Director/Board Member	35	2015-12-31

Nutriband Inc Stock Other OTC

Stocks

US67092M1099

Medical Equipment, Supplies & Distribution

Valuation: Nutriband Inc

Latest news : Nutriband Inc

Press Releases: Nutriband Inc

Managers and Directors: Nutriband Inc

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUTRIBAND INC	-.--%	-.--%	-	-	35.25M
ABBOTT LABORATORIES	-0.66%	-0.95%	-33.96%	-18.86%	154B
MEDTRONIC PLC	-0.09%	-1.38%	-8.19%	-9.31%	102B
HOYA CORPORATION	-0.76%	-1.09%	+57.38%	+59.30%	56.51B
CENCORA, INC.	-0.20%	-3.61%	-7.62%	+44.40%	52.89B
BECTON, DICKINSON AND COMPANY	-2.27%	-3.31%	-16.45%	-45.48%	39.67B
MEDLINE INC.	-3.42%	-7.02%	-	-	30.39B
DEXCOM, INC.	-4.69%	-6.94%	-13.66%	-45.41%	27.96B
WEST PHARMACEUTICAL SERVICES, INC.	+0.54%	-0.52%	+52.77%	-10.57%	23.17B
TERUMO CORPORATION	-2.34%	-1.17%	-17.98%	-3.98%	20.35B
Average	-1.38%	-1.65%	+1.54%	-3.74%	56.28B
Weighted average by Cap.	-1.03%	-1.34%	-7.14%	-3.26%

	2025	2026
Net sales	2.14M 1.87M 1.73M 1.61M 3.03M 202M 3.05M 20.55M 8M 99.41M 8.03M 7.86M 345M	2.04M 1.78M 1.65M 1.54M 2.88M 192M 2.91M 19.56M 7.61M 94.63M 7.65M 7.48M 329M
Net income	-10.48M -9.16M -8.47M -7.91M -14.85M -991M -14.95M -101M -39.17M -487M -39.36M -38.5M -1.69B	-8.23M -7.19M -6.65M -6.21M -11.66M -778M -11.74M -79.04M -30.75M -382M -30.9M -30.23M -1.33B
Net Debt	-4.13M -3.6M -3.33M -3.11M -5.84M -390M -5.89M -39.62M -15.42M -192M -15.49M -15.15M -666M	-4.33M -3.78M -3.5M -3.27M -6.13M -409M -6.18M -41.58M -16.18M -201M -16.25M -15.9M -699M